Why Oppenheimer is Bullish on Tiny Biotech Aprea Therapeutics
Oppenheimer backs Aprea with $5 target. Its cancer drug shows early promise, and low valuation offers big upside potential.
/ 1656 items
#XY↓
Angelini Pharma Buys US Catalyst for $4.1 Billion in State-Backed Deal
Angelini is set to buy US-based Catalyst for $31.50 per share in a state-backed deal, expanding into rare neurological diseases and entering the US market.
Dystrophin Miss Sends Entrada Shares Tumbling Despite Functional Win
Entrada DMD drug was safe and helped movement a bit, but low muscle protein results disappointed investors, stock -60%.
enGene Stock Crashes After Bladder Cancer Drug Shows Solid Safety but Disappointing Durability
enGene bladder cancer drug shows good safety and early response, but weak long-term results; stock drops ~66% after update.
Sarepta Therapeutics Q1 2026 Earnings: Big Beat, But Stock Still Falls
Sarepta reported strong Q1 2026 earnings, with revenue of $730.8M, but shares fell as Elevidys sales dropped 46% due to label restrictions.
Oscar Health Just Had Its Most Profitable Quarter Ever
Oscar Health posted record profit, strong growth, and lower costs, showing a major turnaround and fast expansion.